Uniqure (NASDAQ: QURE) — Perfil da empresa, notícias e dados financeiros
Uniqure develops gene therapies targeting rare diseases, focusing on sustainable treatments with long-lasting benefits.
Uniqure
Uniqure (NASDAQ:QURE) specializes in the development of gene therapies, aiming to deliver transformative treatments for patients suffering from rare diseases. The company leverages its modular platform to address various genetic disorders, with a sharp focus on hemophilia, Huntington's disease, and congestive heart failure. Uniqure's pipeline includes several innovative gene therapy projects in different stages of development, from preclinical studies to late-stage clinical trials. The objective of Uniqure is to pioneer sustainable gene therapies that offer long-lasting benefits to patients with the least amount of treatment-related burden, ultimately improving the quality of life for those affected by challenging genetic conditions. Through its research and development efforts, Uniqure is committed to leading the way in the field of gene therapy and bringing hope to individuals and families impacted by rare diseases.
Resumo
Operações
Produtos e/ou serviços de Uniqure
- Etranacogene dezaparvovec (AMT-061) for Hemophilia B, a gene therapy aimed at providing long-term benefits by introducing a functional gene to produce clotting factor IX.
- AMT-130 for Huntington's disease, a gene therapy designed to lower the levels of huntingtin protein, potentially altering the course of the disease.
- AMT-060, an earlier version of etranacogene dezaparvovec for Hemophilia B, focusing on increasing the production of factor IX to reduce bleeding episodes.
- S100A1 gene therapy project aimed at treating heart failure by introducing a gene to improve heart muscle function.
- AMT-180, an experimental gene therapy for Hemophilia A, aimed to introduce a factor VIII-producing gene to mitigate bleeding risks.
equipe executiva do Uniqure
- Matthew Craig KapustaCEO & Executive Director
- Christian KlemtCFO, Principal Financial Officer & GM of Amsterdam Site
- Jeannette PottsChief Legal & Compliance Officer and Corporate Secretary
- Walid Abi-SaabChief Medical Officer
- Hugo KatusChairman of Scientific Advisory Board and Managing Director of UniQure-Germany
- Amin AbujoubChief Technical Operations Officer
- Richard PorterChief Business & Scientific Officer
- Chiara Elizabeth RussoSenior Director of Investor Relations
- Tamara TugalBusiness Development Director
- Erin BoyerChief People & Culture Officer
Últimas notícias sobre a Uniqure
uniQure reports longer-term Huntington’s disease gene therapy data
United StatesuniQure files Huntington’s disease therapy applications
United StatesuniQure cleared for accelerated approval BLA
United StatesuniQure pivots to Phase 3 planning for Huntington’s after FDA requests sham-controlled trial
United States
Principais indicadores financeiros
Resultados divulgados pela Uniqure , em USD.
- Cap. de mercado
- 1,7 bi
- Receita (TTM)
- 18,7 mi
- P/L
- —
- LPA (diluído, TTM)
- -4.5
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 16,1 mi | -187,8 mi | -199 mi | |
| 27,1 mi | -184,3 mi | -239,6 mi | |
| 15,8 mi | -282,9 mi | -308,5 mi | |
| 106,5 mi | -143,2 mi | -126,8 mi |